SlideShare a Scribd company logo
11th - 14th May, 2024
Lisbon
An educational update from
Dapagliflozin 5 mg / 10 mg
Tablets
Rosuvastatin 40 / 20 / 10 / 5 mg
Spotlights of Day 2
ESC #HeartFailure 2024 Spotlights
1) Evidence-based strategies for guidelines implementations:
Real-world data from registries
Real-world data from registries, including observations from Canada, indicate
stagnant progress in implementing GDMT
Despite various algorithms for quadruple therapy, uncertainty persists in
choosing optimal treatment strategies
The Evolution Heart Failure Registry highlights delayed initiation and high
discontinuation rates for newer therapies like SGLT2 inhibitors and ARNI
ARNI and SGLT2i offer promising avenues for improving HF management.
However, their adoption has been slow, with delayed initiation. The
introduction of ARNI and SGLT2i presents an opportunity to enhance
treatment outcomes, particularly in reducing mortality and optimizing
therapy uptitration
Initiating GDMT is more likely after a heart failure hospitalization,
emphasizing the importance of these events as opportunities for optimization
Barriers to GDMT initiation include older age, renal dysfunction, and low
blood pressure, reflecting real-life challenges
The CAN-AIM study underscores the need for improved GDMT utilization,
especially during hospitalization, where many eligible patients do not receive
appropriate therapy
Implementation considerations suggest slow progress despite the availability
of guideline-recommended therapies
Workforce shortages and limited exposure to heart failure clinics during
training further hinder GDMT optimization
Nudge interventions, such as real-time alerts in electronic health records,
show promise in increasing GDMT prescription rates
Rosuvastatin 40 / 20 / 10 / 5 mg
Dapagliflozin5 mg / 10 mg
Tablets
1
#HeartFailure 2024 Spotlights
ESC
Overall, the data highlight the imperative for enhanced implementation
strategies to optimize GDMT utilization in heart failure patients
Conclusion
Real-world evidence strongly supports the effectiveness of ARNI and SGLT2
inhibitors in managing heart failure, especially with reduced ejection
fraction (HFrEF). These therapies significantly reduce hospitalizations and
mortality rates, providing comprehensive cardiorenal protection and
improving outcomes across diverse patient populations. Their inclusion in
guideline-directed therapy represents a crucial advancement in heart
failure management, promising better patient care and reduced disease
burden
2) Contemporary GDMT sequencing and titration in de novo,
worsening, and chronic HF: first data from the TITRATE-HF study
The guideline recommends rapid titration of drugs for heart failure patients,
with real-world data needed for drug classes implementation
TITRATE-HF study is the first to provide data on the adoption of the new 2021
guidelines for titrating HF medications
The study is a national prospective registry involving 48 participating sites in
the Netherlands, covering about 70% of all Dutch hospitals
The study focused on patients with systolic heart failure, with a mean age of
70, 50% GDMT-naive patients, and about 50% already using GDMT
Side-effects were the principal reasons for reducing GDMT in chronic and
worsening heart failure patients
Rosuvastatin 40 / 20 / 10 / 5 mg
Dapagliflozin5 mg / 10 mg
Tablets
2
#HeartFailure 2024 Spotlights
ESC
Documentation of reasons for non-use of GDMT was lacking in many cases,
with only 20-30% having recorded reasons
Variation in GDMT prescription among participating sites was significant, with
better adherence in dedicated heart failure specialist or nurse specialist
programs
Guideline implementation is an opportunity during hospitalization events, not
only for diuretics but also for optimizing GDMT
Conclusion
GDMT prescription in 2024 showed 44% of patients on quadruple therapy or
1% on target for new drug classes; dedicated heart failure outpatient clinics
help implementation
3) The opportunity of hospitalization and post-discharge
follow-up
Implementation research among hospitalized individuals is crucial as they are
at the highest risk of disease progression, hospitalizations, and death
Hospitalization provides an opportunity to modify risk and optimize
guideline-directed medical therapy (GDMT), with class one recommendations
for pre-discharge and in-hospital optimization
The "nudge ladder" ranges from weaker interventions (provision of
information) to stronger interventions (in-person interventions)
Simple provision of information or flagging high-risk patients in EHR systems is
not sufficient to change decision-making or patient outcomes
Smart EHR nudges, like the Prompt HF intervention, can be successful by
offering tailored suggestions to clinicians based on patient data
Transitional care programs, often nurse-driven, have not shown significant
improvements in implementation or care outcomes in a randomized trial
High-intensity, in-person interventions, like the Strong HF trial, have shown
substantial risk reductions in 180-day readmission and all-cause death but
may not be feasible for all health systems
Rosuvastatin 40 / 20 / 10 / 5 mg
Dapagliflozin5 mg / 10 mg
Tablets
3
#HeartFailure 2024 Spotlights
ESC
High-intensity interventions involve rapid up-titration of GDMT and close
follow-up, resulting in large magnitude risk reductions and improved
outcomes
A middle ground could be centralized, virtual teams reviewing charts and
offering daily recommendations to clinicians, which has shown success in
increasing in-hospital initiation and optimization of GDMT
Post-discharge clinics with less-trained staff optimizing GDMT have also
shown positive results, demonstrating the potential for democratizing care
and involving non-clinicians in the process
Conclusion
Implementation science in the hospitalized high-risk window can improve
heart failure population health through various interventions, including
high-intensity and virtual team approaches
Probability
of
event-free
survival
(%)
Primary endpoint
180-Day Readmission for HF or All-Cause Death
100
95
High intensity care
90
85
80
Usual care
75
180-day risk difference 8.1%
(95% CI 2.9 to 13.2; p=0.0021)
70
0 15 30 45 60 75 90 105 120 135 150 165 180
Time since randomization (days)
Oral HF therapies prescribed in high intensity and usual care
Half to Full optimal dose
High Intensity Care
100
90
80
70
60
50
40
30
20
10
0
Patients
,
(%)
Pre-R a n d D90 D180 D180
ACE/ARBS/ARNI
Pre-R a n d D90
BB
Pre-R a n d D90 D180
MRA
ACEi, angiotensin converting enzyme inhibitors, ARB angiotensin receptors blocker, ARNi angiotensin receptors inhibitors, BB beta blockers, Pre- Rand, pre-randomization
Usual Care
1/2 - Full optimal dose
1/2 - Full optimal dose
Full optimal dose
Full optimal dose
Rosuvastatin 40 / 20 / 10 / 5 mg
Dapagliflozin5 mg / 10 mg
Tablets
4
GDMT clinic patients showed significant improvement in congestion,
reduction in NT-proBNP, and a decrease in overall diuretic use
Safety and tolerability were good, with only two serious adverse events
ESC #HeartFailure 2024 Spotlights
4) TEAM HF- Implementation study of accelerated HF GDMT in a
general cardiology clinic
Despite proven heart failure therapies and guidelines, treatment gaps exist,
with only fewer than 20% of hospitalized heart failure patients receiving
comprehensive GDMT
The Strong HF trial demonstrated the safety and efficacy of rapid
deployment of heart failure therapies among hospitalized patients, but it is
unknown whether this is feasible in a general cardiology clinic setting
The GDMT clinic was established at Massachusetts General Hospital to deliver
optimal treatment for patients in general cardiology, with a team-based
approach involving nurse practitioners, physician assistants, and pharmacists
trained in GDMT titration
The study evaluated the efficacy and safety of the GDMT clinic team-based
approach relative to matched controls treated via usual care
Primary endpoint: The proportion of GDMT clinic patients without
contraindications receiving four-drug GDMT was compared to usual care
Secondary endpoints: The proportion of patients achieving at least 50%
target doses, change in New York Heart Association (NYHA) class, and
NT-proBNP from baseline to the final visit
From baseline to the final visit, the percentage of patients receiving
comprehensive four-drug GDMT increased from 21% to 88% in the GDMT
clinic, compared to no increase in usual care
Rosuvastatin 40 / 20 / 10 / 5 mg
Dapagliflozin5 mg / 10 mg
Tablets
5
#HeartFailure 2024 Spotlights
ESC
Conclusion
The GDMT clinic team-based approach was highly effective and
well-tolerated compared to matched usual care, with the majority of
patients achieving comprehensive four-drug therapy and at least 50%
target doses. Rapid titration resulted in improved heart failure signs and
symptoms despite diuretic dose reduction. The TEAM HF study supports the
feasibility of a Strong HF-like approach to outpatient GDMT administration
for heart failure with impaired ejection fraction, but more data is needed
regarding the benefits of this approach
5) After worsening HF, when to proceed to remote cardiac
monitoring
Congestion remains an issue after hospital discharge, with 48% of patients
having some congestion and 65% experiencing congestion within 60 days
Monitoring pressure dynamics can help detect worsening HF earlier, with
hemodynamic changes occurring almost one month before symptoms and
hospitalization
Hemodynamic monitoring has been shown to reduce hospitalization for heart
failure and the combined endpoint of cardiovascular death and
hospitalization for heart failure
Sacubitril/valsartan and SGLT2 inhibitors have been shown to reduce filling
pressures, highlighting the importance of monitoring pressures even in chronic
patients
EmpagliflozinEffectsonPulmonaryArtery
PressureinPatientsWithHeartFailure
Results From the EMBRACE-HF Trial
65 pts with HFrEF and CardioMems
Early Reduction in Ambulatory Pulmonary
Artery Pressures After Initiation of
Sacubitril/Valsartan
PA
Dastolic
Pressure
(mmHg)
Difference
in
PA
Diastolic
Pressure
(mmHg)
(Empagliflozin
vs.
Placebo)
24
23
22
21
20
19
18
17
16
15
0 1 2 3 4 5 6 7 8 9 10 11 12 13
Weeks
p-value = 0.02
2
1
0
-1
-2
-3
-4
-5
0 1 2 3 4 5 6 7 8 9 10 11 12 13
Weeks
p-value = 0.02
A Effects of Empagliflozin vs. Placebo on Pulmonary B Difference in Pulmonary Artery Diastolic Pressure
Artery Diastolic Pressure between Empagliflozin and Placebo over Time
25 3
Placebo Empagliflozin
Change
in
PAP
from
Baseline
to
30
days
(mm
Hg)
-3.5
-5
-3
-2
-1.5
-2
-2.5
-0.5
0
33 32
-0.2
-2.7
-2.9
-2.1
47 45
-0.4
24 21
-0.0001
Baseline Pressure (mm Hg)
PA mean PA systolic PA diastolic
Sacubitril/Valsartan HFrEF Control
Rosuvastatin 40 / 20 / 10 / 5 mg
Dapagliflozin5 mg / 10 mg
Tablets
6
ESC #HeartFailure 2024 Spotlights
European guidelines suggest that monitoring of pulmonary artery pressures
may be considered for symptomatic patients with heart failure, while US
guidelines recommend pressure monitoring for patients with recent or
recurrent heart failure hospitalization
Limitations of hemodynamic monitoring include invasiveness, need for
anticoagulation, postimplantation complications, resource utilization, time
consumption, and cost
Monitoring congestion through device algorithms or patches has not shown
significant benefits in terms of heart failure hospitalization or mortality
Telemonitoring and telephone support have demonstrated benefits in
reducing mortality and heart failure hospitalization, with telemonitoring being
more suitable for advanced heart failure patients and telephone support for
stable patients
Limitations of telemedicine include digital literacy, human needs, time
consumption, and logistical and bureaucratic issues
Conclusion
Remote cardiac monitoring, particularly hemodynamic and telemedicine
approaches, can positively impact the reduction of heart failure
hospitalization. However, there are doubts regarding their effect on
mortality. Hemodynamic monitoring is more suitable for "frequent fliers"
or advanced heart failure patients, while telemedicine is better for stable
patients. Proactive intervention with effective medical therapy is crucial
for preventing heart failure deterioration
Rosuvastatin 40 / 20 / 10 / 5 mg
Dapagliflozin5 mg / 10 mg
Tablets
7
ESC #HeartFailure 2024 Spotlights
6) Unlocking cardiac health: natriuretic peptides for enhancing
risk prediction, enabling early diagnosis, and guiding
interventions in HF
Natriuretic peptides are established biomarkers for heart failure and are
increasingly recognized as indicators of risk for cardiovascular disease,
particularly heart failure
Natriuretic peptides independently define risk for heart failure and other
cardiovascular diseases, as they reflect the presence of inflammation, fibrosis,
pressure, or volume overload caused by risk factors
The STOP-HF and PONTIAC studies demonstrated that natriuretic
peptide-guided prevention strategies significantly reduced the prevalence of
heart failure stage B, new-onset incident heart failure, and other
cardiovascular events
Guidelines worldwide now recommend natriuretic peptides as a guiding tool
for preventive strategies in heart failure and cardiovascular disease in general
The American Diabetes Association suggests that diabetic patients should
have a natriuretic peptide assessment as part of their routine care, and if
elevated, they should undergo echocardiography
Serial measurements of natriuretic peptides may help identify individuals at
higher risk for incident heart failure and cardiac death
Natriuretic peptides can potentially aid in the earlier diagnosis of heart failure
when used as a screening tool, even if prevention efforts fail
A proposed algorithm incorporates natriuretic peptides into risk assessment,
biomarker triage, and evaluation for early diagnosis of heart failure or other
cardiovascular conditions
Conclusion
Natriuretic peptides play a crucial role in enhancing risk prediction,
enabling early diagnosis, and guiding interventions in heart failure and
cardiovascular disease. By incorporating natriuretic peptides into clinical
algorithms, clinicians can provide more precise, personalized risk
predictions and interventions for patients, ultimately reducing
cardiovascular events and improving patient outcome
Natriuretic Peptide-Guided HF (CV) Risk Modulation
Age, Hypertension,
Diabetes, Vascular
disease, Cardiotoxins,
etc
Normal Level
? Biomarker Review Interval
Enhanced Protection ? Biomarker Review Interval
• SGLT2i
• Finerenone
• Other -ARNI?
Abnormal
Treat
?HF patient
?PAF
General at-risk cohort
NP, Tp, other
Biomarker Triage
Rosuvastatin 40 / 20 / 10 / 5 mg
Dapagliflozin5 mg / 10 mg
Tablets
8
ESC #HeartFailure 2024 Spotlights
7) Combination therapy: Thiazides, acetazolamide, HSS & SGLT2i
Combination therapy with thiazides, acetazolamide, hypertonic saline (HSS),
and SGLT2 inhibitors is recommended for patients with residual congestion
despite routine use of high-dose loop diuretics
The European Society of Cardiology guidelines suggest a sequential
approach to achieve decongestion, but the optimal strategy is unclear
The combination of i.v. furosemide and i.v. acetazolamide was more effective
in reducing weight and congestion at 72 hours than i.v. furosemide alone, but
there was no difference in renal function or clinical outcomes
The ADVOR trial demonstrated that the addition of i.v. acetazolamide to i.v.
furosemide resulted in more successful decongestion at 72 hours and
discharge, with greater urine output and natriuresis
Hypertonic saline solution may improve renal function and diuresis in patients
with diuretic resistance, but its mechanism of action is not well understood
SGLT2 inhibitors, such as empagliflozin and dapagliflozin, have been shown to
enhance diuresis and improve clinical outcomes in patients with heart failure,
both in the short and long-term
Conclusion
Intravenous loop diuretics are the mainstay of therapy for patients with
acute decompensated heart failure, but combination therapy with
thiazides, acetazolamide, HSS, and SGLT2 inhibitors may be more effective
in achieving decongestion and improving clinical outcomes
Adjusted OR: 0.65 (95% CI 0.41-1.02);
P = 0.06
Cumulative
Loop
Diuretic
Dose
(mg)
Cumulative
W
eight
Change
(kg)
Cumulative
Weight
Loss
(kg)/40
mg
IV
Furosemide
Dapagliflozin Usual Care Dapagliflozin Usual Care
P=1.0
0.0
0
-5
-10
-15
-0.5
-1.0
-1.5
Primary Outcome
A
C
B
Cumulative W eight Change
Cumulative Loop Diuretic Dose
4,000
3,000
2,000
1,000
0
Dapagliflozin
Rosuvastatin 40 / 20 / 10 / 5 mg
Dapagliflozin5 mg / 10 mg
Tablets
9
Usual Care
Median 560 m g Median 800 mg
(IQR: 260-1,150) (IQR: 380-1,715)
P = 0.006
N o ↑
adverse
events:
Cardiac, diabetic,
renal and infectious.
The decline in heart failure hospitalizations reported at the beginning of the
century has leveled off, with an increase in younger people and a more
recognized prevalence of heart failure with preserved ejection fraction
Treatment for heart failure hospitalizations shows significant variation
worldwide, with inconsistent use of evidence-based therapies and wide
disparities in length of stay
ESC #HeartFailure 2024 Spotlights
8) State-of-the-art: The conundrum of HF hospitalizations in the
current era
Heart failure hospitalizations represent a complex issue with many questions
surrounding definitions, statistics, and variations in treatment
Defining heart failure hospitalizations can be challenging due to factors such
as primary vs. secondary diagnosis, first-time vs. repeated admissions, and
varying clinical presentations
Heart failure hospitalizations are extremely common, accounting for nearly
as many hospitalizations as myocardial infarction and stroke combined
The statistics on heart failure hospitalizations vary greatly by country and
region, with differences in healthcare provision, data collection, and
definitions contributing to the variability
Rosuvastatin 40 / 20 / 10 / 5 mg
Dapagliflozin5 mg / 10 mg
Tablets
1
0
#HeartFailure 2024 Spotlights
ESC
Outcomes after discharge remain a concern, with variable use of
evidence-based therapies and high between-hospital variability
Readmission and mortality rates are high, with repeated hospitalizations
having a cumulative negative prognostic impact
Addressing the conundrum of heart failure hospitalizations requires focusing
on prevention, facilitating early discharge, improving inpatient care,
monitoring patients for deterioration, and intervening early
Conclusion
Heart failure hospitalizations present a complex and challenging issue in the
current era, with variations in definitions, statistics, and treatment
contributing to the conundrum. To tackle this problem, a comprehensive
approach is needed, focusing on prevention, early discharge, improving
inpatient care, and monitoring patients to detect deterioration and
intervene early. Addressing the variability in evidence-based therapy use
and ensuring adequate decongestion before discharge are crucial aspects
of improving patient outcomes
Rosuvastatin 40 / 20 / 10 / 5 mg
Dapagliflozin5 mg / 10 mg
Tablets
1
1
* HF- Heart Failure
** to reduce the risk of cardiovascular death and hospitalisation for heart failure in adult patients with chronic heart failure.
References
*Imported from the innovator (Novartis); #Significant future risk reduction related to CV/mortality/hospitalisation for HF
1) McMurray et al. N Engl J Med 2014;371(11):993-1004 2 Desai et al. Eur Heart J 2015,36(30) 1990-7 3. Packer et al Circulation 2015,131(1):54-61)
2) Source Haddad H et al. The PARASAIL study-Patient reported outcomes from the Canadian real-world experience use of Vymada in patients with heart failure and reduced ejection fraction, European
Journal of Heart Failure(2017) 19 (Suppl. S1), 34. Source Canu A et al. Results of a single center experience on 200 consecutive patients treated with Entresto (Vymada), European Journal of Heart
Failure(2017) 19 (Suppl S1), 413
THE ONLY* ONE:
Disclaimer: The scientific content herein is crafted by GREY MATTER for JB Pharma, provided for informational purposes. While efforts have been made to ensure accuracy, neither
the authors nor GREY MATTER, its associates, agents, sponsors, or JB Pharma assume liability for errors or inaccuracies. JB Pharma disclaims responsibility for the content's
accuracy, along with all liabilities, including copyright claims. Inclusion/exclusion of products doesn't imply endorsement. Unauthorized reproduction or distribution is prohibited.
Possessors should notify JB Pharma or return the document. Prescription decisions remain the discretion of Registered Medical Practitioners.
Full Prescribing information available on request. For the use of a Registered Medical Practitioner or a Hospital or a Laboratory only.
J.B. Chemicals & Pharmaceuticals Limited
Cnergy IT Park, Unit A, 8th Floor, Appa Saheb Marathe Marg, Prabhadevi, Mumbai – 400025 +91 22 24395200/5500 www.jbpharma.com
INNOVATIVE DRUG DESIGN AND
CO-CRYSTAL LATTICE ENGINEERING
,

More Related Content

Similar to ESC HF 2024 Spotlights Day-2.pptx heart failure

Guideline‐Directed Medical Therapy in HFrEF
Guideline‐Directed Medical Therapy in HFrEFGuideline‐Directed Medical Therapy in HFrEF
Guideline‐Directed Medical Therapy in HFrEF
Kerolus Shehata
 
lipid lowering therapy heart disease
lipid lowering therapy heart diseaselipid lowering therapy heart disease
lipid lowering therapy heart disease
reygais
 
Part 2 MHFS, how to build MDHFP
Part 2 MHFS, how to build MDHFPPart 2 MHFS, how to build MDHFP
Part 2 MHFS, how to build MDHFP
asadsoomro1960
 
FIGARO-DKD-Presentation.pptx
FIGARO-DKD-Presentation.pptxFIGARO-DKD-Presentation.pptx
FIGARO-DKD-Presentation.pptx
JackJack424700
 
Simultaneous or Rapid Sequence Initiation of Quadruple Therapy for HFrEF
Simultaneous or Rapid Sequence Initiation of Quadruple Therapy for HFrEFSimultaneous or Rapid Sequence Initiation of Quadruple Therapy for HFrEF
Simultaneous or Rapid Sequence Initiation of Quadruple Therapy for HFrEF
Duke Heart
 
Diabetes MedInsights
Diabetes MedInsightsDiabetes MedInsights
Diabetes MedInsights
Lydia Green, RPh
 
The unmet needs of patients with heart failure meeting 17 Feb 2022.pptx
The unmet needs of patients with heart failure meeting  17 Feb 2022.pptxThe unmet needs of patients with heart failure meeting  17 Feb 2022.pptx
The unmet needs of patients with heart failure meeting 17 Feb 2022.pptx
AdelSALLAM4
 
The unmet needs of patients with heart failure meeting 17 Feb 2022.pptx
The unmet needs of patients with heart failure meeting  17 Feb 2022.pptxThe unmet needs of patients with heart failure meeting  17 Feb 2022.pptx
The unmet needs of patients with heart failure meeting 17 Feb 2022.pptx
AdelSALLAM4
 
NAFLD Patients have Limited Access to GLP1 Agonists and SGLT2 Inhibitors: NHA...
NAFLD Patients have Limited Access to GLP1 Agonists and SGLT2 Inhibitors: NHA...NAFLD Patients have Limited Access to GLP1 Agonists and SGLT2 Inhibitors: NHA...
NAFLD Patients have Limited Access to GLP1 Agonists and SGLT2 Inhibitors: NHA...
JohnJulie1
 
Which I.V. therapies work in HHF ?
Which I.V. therapies work in HHF ?Which I.V. therapies work in HHF ?
Which I.V. therapies work in HHF ?
drucsamal
 
Key Slides on Individualizing ART Management Based on Treatment Safety and To...
Key Slides on Individualizing ART Management Based on Treatment Safety and To...Key Slides on Individualizing ART Management Based on Treatment Safety and To...
Key Slides on Individualizing ART Management Based on Treatment Safety and To...
hivlifeinfo
 
arni hf.pptx
arni hf.pptxarni hf.pptx
arni hf.pptx
ShoaibKhatik3
 
SGLT2 inhibitors
SGLT2 inhibitorsSGLT2 inhibitors
SGLT2 inhibitors
AhmedElBorae1
 
AFFIRM trial JC NOVANT
AFFIRM trial JC NOVANTAFFIRM trial JC NOVANT
AFFIRM trial JC NOVANT
Elmira Darvish
 
MCO 2011 - Slide 19 - M. Aapro - Spotlight session - EORTC G-CSF Guidelines -...
MCO 2011 - Slide 19 - M. Aapro - Spotlight session - EORTC G-CSF Guidelines -...MCO 2011 - Slide 19 - M. Aapro - Spotlight session - EORTC G-CSF Guidelines -...
MCO 2011 - Slide 19 - M. Aapro - Spotlight session - EORTC G-CSF Guidelines -...
European School of Oncology
 
Merge Journal Club 2 Background + method.pdf
Merge Journal Club 2 Background + method.pdfMerge Journal Club 2 Background + method.pdf
Merge Journal Club 2 Background + method.pdf
MyThaoAiDoan
 
Horizontal or Vertical Approach in Starting Fantastic Four (Revised).pptx
Horizontal or Vertical Approach in Starting Fantastic Four (Revised).pptxHorizontal or Vertical Approach in Starting Fantastic Four (Revised).pptx
Horizontal or Vertical Approach in Starting Fantastic Four (Revised).pptx
ParikshitMishra15
 
effects of-interactive-patient-smartphone
effects of-interactive-patient-smartphoneeffects of-interactive-patient-smartphone
effects of-interactive-patient-smartphone
د حاتم البيطار
 
Renal Denervation in Resistant Hypertension 23.pptx
Renal Denervation in Resistant Hypertension 23.pptxRenal Denervation in Resistant Hypertension 23.pptx
Renal Denervation in Resistant Hypertension 23.pptx
Prerna806536
 
Kedev S - AIMRADIAL 2013 - Renal denervation
Kedev S - AIMRADIAL 2013 - Renal denervationKedev S - AIMRADIAL 2013 - Renal denervation

Similar to ESC HF 2024 Spotlights Day-2.pptx heart failure (20)

Guideline‐Directed Medical Therapy in HFrEF
Guideline‐Directed Medical Therapy in HFrEFGuideline‐Directed Medical Therapy in HFrEF
Guideline‐Directed Medical Therapy in HFrEF
 
lipid lowering therapy heart disease
lipid lowering therapy heart diseaselipid lowering therapy heart disease
lipid lowering therapy heart disease
 
Part 2 MHFS, how to build MDHFP
Part 2 MHFS, how to build MDHFPPart 2 MHFS, how to build MDHFP
Part 2 MHFS, how to build MDHFP
 
FIGARO-DKD-Presentation.pptx
FIGARO-DKD-Presentation.pptxFIGARO-DKD-Presentation.pptx
FIGARO-DKD-Presentation.pptx
 
Simultaneous or Rapid Sequence Initiation of Quadruple Therapy for HFrEF
Simultaneous or Rapid Sequence Initiation of Quadruple Therapy for HFrEFSimultaneous or Rapid Sequence Initiation of Quadruple Therapy for HFrEF
Simultaneous or Rapid Sequence Initiation of Quadruple Therapy for HFrEF
 
Diabetes MedInsights
Diabetes MedInsightsDiabetes MedInsights
Diabetes MedInsights
 
The unmet needs of patients with heart failure meeting 17 Feb 2022.pptx
The unmet needs of patients with heart failure meeting  17 Feb 2022.pptxThe unmet needs of patients with heart failure meeting  17 Feb 2022.pptx
The unmet needs of patients with heart failure meeting 17 Feb 2022.pptx
 
The unmet needs of patients with heart failure meeting 17 Feb 2022.pptx
The unmet needs of patients with heart failure meeting  17 Feb 2022.pptxThe unmet needs of patients with heart failure meeting  17 Feb 2022.pptx
The unmet needs of patients with heart failure meeting 17 Feb 2022.pptx
 
NAFLD Patients have Limited Access to GLP1 Agonists and SGLT2 Inhibitors: NHA...
NAFLD Patients have Limited Access to GLP1 Agonists and SGLT2 Inhibitors: NHA...NAFLD Patients have Limited Access to GLP1 Agonists and SGLT2 Inhibitors: NHA...
NAFLD Patients have Limited Access to GLP1 Agonists and SGLT2 Inhibitors: NHA...
 
Which I.V. therapies work in HHF ?
Which I.V. therapies work in HHF ?Which I.V. therapies work in HHF ?
Which I.V. therapies work in HHF ?
 
Key Slides on Individualizing ART Management Based on Treatment Safety and To...
Key Slides on Individualizing ART Management Based on Treatment Safety and To...Key Slides on Individualizing ART Management Based on Treatment Safety and To...
Key Slides on Individualizing ART Management Based on Treatment Safety and To...
 
arni hf.pptx
arni hf.pptxarni hf.pptx
arni hf.pptx
 
SGLT2 inhibitors
SGLT2 inhibitorsSGLT2 inhibitors
SGLT2 inhibitors
 
AFFIRM trial JC NOVANT
AFFIRM trial JC NOVANTAFFIRM trial JC NOVANT
AFFIRM trial JC NOVANT
 
MCO 2011 - Slide 19 - M. Aapro - Spotlight session - EORTC G-CSF Guidelines -...
MCO 2011 - Slide 19 - M. Aapro - Spotlight session - EORTC G-CSF Guidelines -...MCO 2011 - Slide 19 - M. Aapro - Spotlight session - EORTC G-CSF Guidelines -...
MCO 2011 - Slide 19 - M. Aapro - Spotlight session - EORTC G-CSF Guidelines -...
 
Merge Journal Club 2 Background + method.pdf
Merge Journal Club 2 Background + method.pdfMerge Journal Club 2 Background + method.pdf
Merge Journal Club 2 Background + method.pdf
 
Horizontal or Vertical Approach in Starting Fantastic Four (Revised).pptx
Horizontal or Vertical Approach in Starting Fantastic Four (Revised).pptxHorizontal or Vertical Approach in Starting Fantastic Four (Revised).pptx
Horizontal or Vertical Approach in Starting Fantastic Four (Revised).pptx
 
effects of-interactive-patient-smartphone
effects of-interactive-patient-smartphoneeffects of-interactive-patient-smartphone
effects of-interactive-patient-smartphone
 
Renal Denervation in Resistant Hypertension 23.pptx
Renal Denervation in Resistant Hypertension 23.pptxRenal Denervation in Resistant Hypertension 23.pptx
Renal Denervation in Resistant Hypertension 23.pptx
 
Kedev S - AIMRADIAL 2013 - Renal denervation
Kedev S - AIMRADIAL 2013 - Renal denervationKedev S - AIMRADIAL 2013 - Renal denervation
Kedev S - AIMRADIAL 2013 - Renal denervation
 

Recently uploaded

Best Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and IndigestionBest Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and Indigestion
Swastik Ayurveda
 
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
FFragrant
 
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradeshBasavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Dr. Madduru Muni Haritha
 
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeNovas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Prof. Marcus Renato de Carvalho
 
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in IndiaTop 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Swastik Ayurveda
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
suvadeepdas911
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
rishi2789
 
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptxVestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Oleg Kshivets
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Saeid Safari
 
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptxThyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
Dr. Jyothirmai Paindla
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
Tina Purnat
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
rishi2789
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
taiba qazi
 
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
rishi2789
 
Adhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.comAdhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.com
reignlana06
 
Management of Traumatic Splenic injury.pptx
Management of Traumatic Splenic injury.pptxManagement of Traumatic Splenic injury.pptx
Management of Traumatic Splenic injury.pptx
AkshaySarraf1
 
Knee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdfKnee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdf
vimalpl1234
 
The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
MedicoseAcademics
 

Recently uploaded (20)

Best Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and IndigestionBest Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and Indigestion
 
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
 
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradeshBasavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
 
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeNovas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
 
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in IndiaTop 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in India
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
 
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptxVestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
 
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptxThyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
 
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
 
Adhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.comAdhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.com
 
Management of Traumatic Splenic injury.pptx
Management of Traumatic Splenic injury.pptxManagement of Traumatic Splenic injury.pptx
Management of Traumatic Splenic injury.pptx
 
Knee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdfKnee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdf
 
The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
 

ESC HF 2024 Spotlights Day-2.pptx heart failure

  • 1. 11th - 14th May, 2024 Lisbon An educational update from Dapagliflozin 5 mg / 10 mg Tablets Rosuvastatin 40 / 20 / 10 / 5 mg Spotlights of Day 2
  • 2. ESC #HeartFailure 2024 Spotlights 1) Evidence-based strategies for guidelines implementations: Real-world data from registries Real-world data from registries, including observations from Canada, indicate stagnant progress in implementing GDMT Despite various algorithms for quadruple therapy, uncertainty persists in choosing optimal treatment strategies The Evolution Heart Failure Registry highlights delayed initiation and high discontinuation rates for newer therapies like SGLT2 inhibitors and ARNI ARNI and SGLT2i offer promising avenues for improving HF management. However, their adoption has been slow, with delayed initiation. The introduction of ARNI and SGLT2i presents an opportunity to enhance treatment outcomes, particularly in reducing mortality and optimizing therapy uptitration Initiating GDMT is more likely after a heart failure hospitalization, emphasizing the importance of these events as opportunities for optimization Barriers to GDMT initiation include older age, renal dysfunction, and low blood pressure, reflecting real-life challenges The CAN-AIM study underscores the need for improved GDMT utilization, especially during hospitalization, where many eligible patients do not receive appropriate therapy Implementation considerations suggest slow progress despite the availability of guideline-recommended therapies Workforce shortages and limited exposure to heart failure clinics during training further hinder GDMT optimization Nudge interventions, such as real-time alerts in electronic health records, show promise in increasing GDMT prescription rates Rosuvastatin 40 / 20 / 10 / 5 mg Dapagliflozin5 mg / 10 mg Tablets 1
  • 3. #HeartFailure 2024 Spotlights ESC Overall, the data highlight the imperative for enhanced implementation strategies to optimize GDMT utilization in heart failure patients Conclusion Real-world evidence strongly supports the effectiveness of ARNI and SGLT2 inhibitors in managing heart failure, especially with reduced ejection fraction (HFrEF). These therapies significantly reduce hospitalizations and mortality rates, providing comprehensive cardiorenal protection and improving outcomes across diverse patient populations. Their inclusion in guideline-directed therapy represents a crucial advancement in heart failure management, promising better patient care and reduced disease burden 2) Contemporary GDMT sequencing and titration in de novo, worsening, and chronic HF: first data from the TITRATE-HF study The guideline recommends rapid titration of drugs for heart failure patients, with real-world data needed for drug classes implementation TITRATE-HF study is the first to provide data on the adoption of the new 2021 guidelines for titrating HF medications The study is a national prospective registry involving 48 participating sites in the Netherlands, covering about 70% of all Dutch hospitals The study focused on patients with systolic heart failure, with a mean age of 70, 50% GDMT-naive patients, and about 50% already using GDMT Side-effects were the principal reasons for reducing GDMT in chronic and worsening heart failure patients Rosuvastatin 40 / 20 / 10 / 5 mg Dapagliflozin5 mg / 10 mg Tablets 2
  • 4. #HeartFailure 2024 Spotlights ESC Documentation of reasons for non-use of GDMT was lacking in many cases, with only 20-30% having recorded reasons Variation in GDMT prescription among participating sites was significant, with better adherence in dedicated heart failure specialist or nurse specialist programs Guideline implementation is an opportunity during hospitalization events, not only for diuretics but also for optimizing GDMT Conclusion GDMT prescription in 2024 showed 44% of patients on quadruple therapy or 1% on target for new drug classes; dedicated heart failure outpatient clinics help implementation 3) The opportunity of hospitalization and post-discharge follow-up Implementation research among hospitalized individuals is crucial as they are at the highest risk of disease progression, hospitalizations, and death Hospitalization provides an opportunity to modify risk and optimize guideline-directed medical therapy (GDMT), with class one recommendations for pre-discharge and in-hospital optimization The "nudge ladder" ranges from weaker interventions (provision of information) to stronger interventions (in-person interventions) Simple provision of information or flagging high-risk patients in EHR systems is not sufficient to change decision-making or patient outcomes Smart EHR nudges, like the Prompt HF intervention, can be successful by offering tailored suggestions to clinicians based on patient data Transitional care programs, often nurse-driven, have not shown significant improvements in implementation or care outcomes in a randomized trial High-intensity, in-person interventions, like the Strong HF trial, have shown substantial risk reductions in 180-day readmission and all-cause death but may not be feasible for all health systems Rosuvastatin 40 / 20 / 10 / 5 mg Dapagliflozin5 mg / 10 mg Tablets 3
  • 5. #HeartFailure 2024 Spotlights ESC High-intensity interventions involve rapid up-titration of GDMT and close follow-up, resulting in large magnitude risk reductions and improved outcomes A middle ground could be centralized, virtual teams reviewing charts and offering daily recommendations to clinicians, which has shown success in increasing in-hospital initiation and optimization of GDMT Post-discharge clinics with less-trained staff optimizing GDMT have also shown positive results, demonstrating the potential for democratizing care and involving non-clinicians in the process Conclusion Implementation science in the hospitalized high-risk window can improve heart failure population health through various interventions, including high-intensity and virtual team approaches Probability of event-free survival (%) Primary endpoint 180-Day Readmission for HF or All-Cause Death 100 95 High intensity care 90 85 80 Usual care 75 180-day risk difference 8.1% (95% CI 2.9 to 13.2; p=0.0021) 70 0 15 30 45 60 75 90 105 120 135 150 165 180 Time since randomization (days) Oral HF therapies prescribed in high intensity and usual care Half to Full optimal dose High Intensity Care 100 90 80 70 60 50 40 30 20 10 0 Patients , (%) Pre-R a n d D90 D180 D180 ACE/ARBS/ARNI Pre-R a n d D90 BB Pre-R a n d D90 D180 MRA ACEi, angiotensin converting enzyme inhibitors, ARB angiotensin receptors blocker, ARNi angiotensin receptors inhibitors, BB beta blockers, Pre- Rand, pre-randomization Usual Care 1/2 - Full optimal dose 1/2 - Full optimal dose Full optimal dose Full optimal dose Rosuvastatin 40 / 20 / 10 / 5 mg Dapagliflozin5 mg / 10 mg Tablets 4
  • 6. GDMT clinic patients showed significant improvement in congestion, reduction in NT-proBNP, and a decrease in overall diuretic use Safety and tolerability were good, with only two serious adverse events ESC #HeartFailure 2024 Spotlights 4) TEAM HF- Implementation study of accelerated HF GDMT in a general cardiology clinic Despite proven heart failure therapies and guidelines, treatment gaps exist, with only fewer than 20% of hospitalized heart failure patients receiving comprehensive GDMT The Strong HF trial demonstrated the safety and efficacy of rapid deployment of heart failure therapies among hospitalized patients, but it is unknown whether this is feasible in a general cardiology clinic setting The GDMT clinic was established at Massachusetts General Hospital to deliver optimal treatment for patients in general cardiology, with a team-based approach involving nurse practitioners, physician assistants, and pharmacists trained in GDMT titration The study evaluated the efficacy and safety of the GDMT clinic team-based approach relative to matched controls treated via usual care Primary endpoint: The proportion of GDMT clinic patients without contraindications receiving four-drug GDMT was compared to usual care Secondary endpoints: The proportion of patients achieving at least 50% target doses, change in New York Heart Association (NYHA) class, and NT-proBNP from baseline to the final visit From baseline to the final visit, the percentage of patients receiving comprehensive four-drug GDMT increased from 21% to 88% in the GDMT clinic, compared to no increase in usual care Rosuvastatin 40 / 20 / 10 / 5 mg Dapagliflozin5 mg / 10 mg Tablets 5
  • 7. #HeartFailure 2024 Spotlights ESC Conclusion The GDMT clinic team-based approach was highly effective and well-tolerated compared to matched usual care, with the majority of patients achieving comprehensive four-drug therapy and at least 50% target doses. Rapid titration resulted in improved heart failure signs and symptoms despite diuretic dose reduction. The TEAM HF study supports the feasibility of a Strong HF-like approach to outpatient GDMT administration for heart failure with impaired ejection fraction, but more data is needed regarding the benefits of this approach 5) After worsening HF, when to proceed to remote cardiac monitoring Congestion remains an issue after hospital discharge, with 48% of patients having some congestion and 65% experiencing congestion within 60 days Monitoring pressure dynamics can help detect worsening HF earlier, with hemodynamic changes occurring almost one month before symptoms and hospitalization Hemodynamic monitoring has been shown to reduce hospitalization for heart failure and the combined endpoint of cardiovascular death and hospitalization for heart failure Sacubitril/valsartan and SGLT2 inhibitors have been shown to reduce filling pressures, highlighting the importance of monitoring pressures even in chronic patients EmpagliflozinEffectsonPulmonaryArtery PressureinPatientsWithHeartFailure Results From the EMBRACE-HF Trial 65 pts with HFrEF and CardioMems Early Reduction in Ambulatory Pulmonary Artery Pressures After Initiation of Sacubitril/Valsartan PA Dastolic Pressure (mmHg) Difference in PA Diastolic Pressure (mmHg) (Empagliflozin vs. Placebo) 24 23 22 21 20 19 18 17 16 15 0 1 2 3 4 5 6 7 8 9 10 11 12 13 Weeks p-value = 0.02 2 1 0 -1 -2 -3 -4 -5 0 1 2 3 4 5 6 7 8 9 10 11 12 13 Weeks p-value = 0.02 A Effects of Empagliflozin vs. Placebo on Pulmonary B Difference in Pulmonary Artery Diastolic Pressure Artery Diastolic Pressure between Empagliflozin and Placebo over Time 25 3 Placebo Empagliflozin Change in PAP from Baseline to 30 days (mm Hg) -3.5 -5 -3 -2 -1.5 -2 -2.5 -0.5 0 33 32 -0.2 -2.7 -2.9 -2.1 47 45 -0.4 24 21 -0.0001 Baseline Pressure (mm Hg) PA mean PA systolic PA diastolic Sacubitril/Valsartan HFrEF Control Rosuvastatin 40 / 20 / 10 / 5 mg Dapagliflozin5 mg / 10 mg Tablets 6
  • 8. ESC #HeartFailure 2024 Spotlights European guidelines suggest that monitoring of pulmonary artery pressures may be considered for symptomatic patients with heart failure, while US guidelines recommend pressure monitoring for patients with recent or recurrent heart failure hospitalization Limitations of hemodynamic monitoring include invasiveness, need for anticoagulation, postimplantation complications, resource utilization, time consumption, and cost Monitoring congestion through device algorithms or patches has not shown significant benefits in terms of heart failure hospitalization or mortality Telemonitoring and telephone support have demonstrated benefits in reducing mortality and heart failure hospitalization, with telemonitoring being more suitable for advanced heart failure patients and telephone support for stable patients Limitations of telemedicine include digital literacy, human needs, time consumption, and logistical and bureaucratic issues Conclusion Remote cardiac monitoring, particularly hemodynamic and telemedicine approaches, can positively impact the reduction of heart failure hospitalization. However, there are doubts regarding their effect on mortality. Hemodynamic monitoring is more suitable for "frequent fliers" or advanced heart failure patients, while telemedicine is better for stable patients. Proactive intervention with effective medical therapy is crucial for preventing heart failure deterioration Rosuvastatin 40 / 20 / 10 / 5 mg Dapagliflozin5 mg / 10 mg Tablets 7
  • 9. ESC #HeartFailure 2024 Spotlights 6) Unlocking cardiac health: natriuretic peptides for enhancing risk prediction, enabling early diagnosis, and guiding interventions in HF Natriuretic peptides are established biomarkers for heart failure and are increasingly recognized as indicators of risk for cardiovascular disease, particularly heart failure Natriuretic peptides independently define risk for heart failure and other cardiovascular diseases, as they reflect the presence of inflammation, fibrosis, pressure, or volume overload caused by risk factors The STOP-HF and PONTIAC studies demonstrated that natriuretic peptide-guided prevention strategies significantly reduced the prevalence of heart failure stage B, new-onset incident heart failure, and other cardiovascular events Guidelines worldwide now recommend natriuretic peptides as a guiding tool for preventive strategies in heart failure and cardiovascular disease in general The American Diabetes Association suggests that diabetic patients should have a natriuretic peptide assessment as part of their routine care, and if elevated, they should undergo echocardiography Serial measurements of natriuretic peptides may help identify individuals at higher risk for incident heart failure and cardiac death Natriuretic peptides can potentially aid in the earlier diagnosis of heart failure when used as a screening tool, even if prevention efforts fail A proposed algorithm incorporates natriuretic peptides into risk assessment, biomarker triage, and evaluation for early diagnosis of heart failure or other cardiovascular conditions Conclusion Natriuretic peptides play a crucial role in enhancing risk prediction, enabling early diagnosis, and guiding interventions in heart failure and cardiovascular disease. By incorporating natriuretic peptides into clinical algorithms, clinicians can provide more precise, personalized risk predictions and interventions for patients, ultimately reducing cardiovascular events and improving patient outcome Natriuretic Peptide-Guided HF (CV) Risk Modulation Age, Hypertension, Diabetes, Vascular disease, Cardiotoxins, etc Normal Level ? Biomarker Review Interval Enhanced Protection ? Biomarker Review Interval • SGLT2i • Finerenone • Other -ARNI? Abnormal Treat ?HF patient ?PAF General at-risk cohort NP, Tp, other Biomarker Triage Rosuvastatin 40 / 20 / 10 / 5 mg Dapagliflozin5 mg / 10 mg Tablets 8
  • 10. ESC #HeartFailure 2024 Spotlights 7) Combination therapy: Thiazides, acetazolamide, HSS & SGLT2i Combination therapy with thiazides, acetazolamide, hypertonic saline (HSS), and SGLT2 inhibitors is recommended for patients with residual congestion despite routine use of high-dose loop diuretics The European Society of Cardiology guidelines suggest a sequential approach to achieve decongestion, but the optimal strategy is unclear The combination of i.v. furosemide and i.v. acetazolamide was more effective in reducing weight and congestion at 72 hours than i.v. furosemide alone, but there was no difference in renal function or clinical outcomes The ADVOR trial demonstrated that the addition of i.v. acetazolamide to i.v. furosemide resulted in more successful decongestion at 72 hours and discharge, with greater urine output and natriuresis Hypertonic saline solution may improve renal function and diuresis in patients with diuretic resistance, but its mechanism of action is not well understood SGLT2 inhibitors, such as empagliflozin and dapagliflozin, have been shown to enhance diuresis and improve clinical outcomes in patients with heart failure, both in the short and long-term Conclusion Intravenous loop diuretics are the mainstay of therapy for patients with acute decompensated heart failure, but combination therapy with thiazides, acetazolamide, HSS, and SGLT2 inhibitors may be more effective in achieving decongestion and improving clinical outcomes Adjusted OR: 0.65 (95% CI 0.41-1.02); P = 0.06 Cumulative Loop Diuretic Dose (mg) Cumulative W eight Change (kg) Cumulative Weight Loss (kg)/40 mg IV Furosemide Dapagliflozin Usual Care Dapagliflozin Usual Care P=1.0 0.0 0 -5 -10 -15 -0.5 -1.0 -1.5 Primary Outcome A C B Cumulative W eight Change Cumulative Loop Diuretic Dose 4,000 3,000 2,000 1,000 0 Dapagliflozin Rosuvastatin 40 / 20 / 10 / 5 mg Dapagliflozin5 mg / 10 mg Tablets 9 Usual Care Median 560 m g Median 800 mg (IQR: 260-1,150) (IQR: 380-1,715) P = 0.006 N o ↑ adverse events: Cardiac, diabetic, renal and infectious.
  • 11. The decline in heart failure hospitalizations reported at the beginning of the century has leveled off, with an increase in younger people and a more recognized prevalence of heart failure with preserved ejection fraction Treatment for heart failure hospitalizations shows significant variation worldwide, with inconsistent use of evidence-based therapies and wide disparities in length of stay ESC #HeartFailure 2024 Spotlights 8) State-of-the-art: The conundrum of HF hospitalizations in the current era Heart failure hospitalizations represent a complex issue with many questions surrounding definitions, statistics, and variations in treatment Defining heart failure hospitalizations can be challenging due to factors such as primary vs. secondary diagnosis, first-time vs. repeated admissions, and varying clinical presentations Heart failure hospitalizations are extremely common, accounting for nearly as many hospitalizations as myocardial infarction and stroke combined The statistics on heart failure hospitalizations vary greatly by country and region, with differences in healthcare provision, data collection, and definitions contributing to the variability Rosuvastatin 40 / 20 / 10 / 5 mg Dapagliflozin5 mg / 10 mg Tablets 1 0
  • 12. #HeartFailure 2024 Spotlights ESC Outcomes after discharge remain a concern, with variable use of evidence-based therapies and high between-hospital variability Readmission and mortality rates are high, with repeated hospitalizations having a cumulative negative prognostic impact Addressing the conundrum of heart failure hospitalizations requires focusing on prevention, facilitating early discharge, improving inpatient care, monitoring patients for deterioration, and intervening early Conclusion Heart failure hospitalizations present a complex and challenging issue in the current era, with variations in definitions, statistics, and treatment contributing to the conundrum. To tackle this problem, a comprehensive approach is needed, focusing on prevention, early discharge, improving inpatient care, and monitoring patients to detect deterioration and intervene early. Addressing the variability in evidence-based therapy use and ensuring adequate decongestion before discharge are crucial aspects of improving patient outcomes Rosuvastatin 40 / 20 / 10 / 5 mg Dapagliflozin5 mg / 10 mg Tablets 1 1
  • 13. * HF- Heart Failure ** to reduce the risk of cardiovascular death and hospitalisation for heart failure in adult patients with chronic heart failure. References *Imported from the innovator (Novartis); #Significant future risk reduction related to CV/mortality/hospitalisation for HF 1) McMurray et al. N Engl J Med 2014;371(11):993-1004 2 Desai et al. Eur Heart J 2015,36(30) 1990-7 3. Packer et al Circulation 2015,131(1):54-61) 2) Source Haddad H et al. The PARASAIL study-Patient reported outcomes from the Canadian real-world experience use of Vymada in patients with heart failure and reduced ejection fraction, European Journal of Heart Failure(2017) 19 (Suppl. S1), 34. Source Canu A et al. Results of a single center experience on 200 consecutive patients treated with Entresto (Vymada), European Journal of Heart Failure(2017) 19 (Suppl S1), 413 THE ONLY* ONE: Disclaimer: The scientific content herein is crafted by GREY MATTER for JB Pharma, provided for informational purposes. While efforts have been made to ensure accuracy, neither the authors nor GREY MATTER, its associates, agents, sponsors, or JB Pharma assume liability for errors or inaccuracies. JB Pharma disclaims responsibility for the content's accuracy, along with all liabilities, including copyright claims. Inclusion/exclusion of products doesn't imply endorsement. Unauthorized reproduction or distribution is prohibited. Possessors should notify JB Pharma or return the document. Prescription decisions remain the discretion of Registered Medical Practitioners. Full Prescribing information available on request. For the use of a Registered Medical Practitioner or a Hospital or a Laboratory only. J.B. Chemicals & Pharmaceuticals Limited Cnergy IT Park, Unit A, 8th Floor, Appa Saheb Marathe Marg, Prabhadevi, Mumbai – 400025 +91 22 24395200/5500 www.jbpharma.com INNOVATIVE DRUG DESIGN AND CO-CRYSTAL LATTICE ENGINEERING ,